Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28302263 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL9092266 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL14125873 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL1116216 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL20746352 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL20746322 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL3689153 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL6011969 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL6011884 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| Potassium SCHEMBL29838772 | 0.97 | ALDH1A1 (0.56) | ALDH1A1TDP1LMNACYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226215-A1 | NOVEL RECOMBINANT EXOSOME AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-07-20 | — | — | US | disclosed |
| US-20230173099-A1 | LIPOLYSIS COMPOSITION USING SURFACE-MODIFIED GAS-GENERATING NANOPARTICLES | SUPERNOVA BIO CO., LTD. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-11518735-B2 | Pseudoceramide compound with improved stability and composition comprising same | AE KYUNG INDUSTRIAL CO., LTD. (KR) | 2022-12-06 | — | — | US | disclosed |
| CN-112703184-A | Process for producing amide compound, and amide compound | 广荣化学株式会社 | 2021-04-23 | — | — | CN | disclosed |
| US-20200354309-A1 | NOVEL PSEUDOCERAMIDE COMPOUND WITH IMPROVED STABILITY AND COMPOSITION COMPRISING SAME | AE KYUNG INDUSTRIAL CO., LTD (KR) | 2020-11-12 | — | — | US | disclosed |
| US-10722548-B2 | Method of preparing lyophilizate of Taheebo alcohol extract | COSMAX NBT, INC. (KR) | 2020-07-28 | — | — | US | disclosed |
| US-10695314-B2 | Antimicrobial composition containing 7,10-epoxyoctadeca-7,9-dienoic acid as active ingredient | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2020-06-30 | — | — | US | disclosed |
| CN-105392492-B | Composition for preventing hair loss or promoting hair growth containing wheat bran extract as active ingredient | 济州大学校产学协力团 | 2020-04-21 | — | — | CN | disclosed |
| US-20190167746-A1 | METHOD OF PREPARING LYOPHILIZATE OF TAHEEBO ALCOHOL EXTRACT | NUTRIBIOTECH (KR) | 2019-06-06 | — | — | US | disclosed |
| US-20190133989-A1 | ANTIMICROBIAL COMPOSITION CONTAINING 7,10-EPOXYOCTADECA-7,9-DIENOIC ACID AS ACTIVE INGREDIENT | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2019-05-09 | — | — | US | disclosed |
| US-10233143-B2 | Pseudoceramide compound, and external use skin preparation composition containing same | AE KYUNG INDUSTRIAL CO., LTD (KR) | 2019-03-19 | — | — | US | disclosed |
| US-20170313648-A1 | NOVEL PSEUDOCERAMIDE COMPOUND, AND EXTERNAL USE SKIN PREPARATION COMPOSITION CONTAINING SAME | AE KYUNG INDUSTRIAL CO., LTD (KR) | 2017-11-02 | — | — | US | disclosed |
| US-20120129838-A1 | Composition for Preventing and Treating Alopecia Disorder Containing Morgalanthamine Compounds as an Active Ingredient | THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (KR) | 2012-05-24 | — | — | US | disclosed |
| US-7618950-B2 | Using 5-[(E)-2-halogenovinyl] arabinofuranosyl uracil; sorivudine | ARIGEN PHARMACEUTICALS, INC. (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20060009401-A1 | Method for treatment and prevention of herpes zoster by topical application | ARIGEN, INC. (JP) | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129838-A1 | Composition for Preventing and Treating Alopecia Disorder Containing Morgalanthamine Compounds as an Active Ingredient | MITF, GLA, GALNT3 | ALDH1A1 713/4885TDP1 2831/4885LMNA 1602/4885 |
| US-11518735-B2 | Pseudoceramide compound with improved stability and composition comprising same | CERS2, ASAH2, ASAH1 | ALDH1A1 3212/4885TDP1 2311/4885LMNA 2931/4885 |
| US-20200354309-A1 | NOVEL PSEUDOCERAMIDE COMPOUND WITH IMPROVED STABILITY AND COMPOSITION COMPRISING SAME | CERS2, ASAH2, CERT1 | ALDH1A1 3159/4885TDP1 2418/4885LMNA 3151/4885 |
| US-10695314-B2 | Antimicrobial composition containing 7,10-epoxyoctadeca-7,9-dienoic acid as active ingredient | CYP51A1, IL17A, ELOVL5 | ALDH1A1 812/4885TDP1 3363/4885LMNA 3299/4885 |
| US-20060009401-A1 | Method for treatment and prevention of herpes zoster by topical application | UNG, XDH, TK1 | ALDH1A1 1747/4885TDP1 372/4885LMNA 4119/4885 |
| US-20190133989-A1 | ANTIMICROBIAL COMPOSITION CONTAINING 7,10-EPOXYOCTADECA-7,9-DIENOIC ACID AS ACTIVE INGREDIENT | CYP51A1, IL17A, ELOVL5 | ALDH1A1 812/4885TDP1 3363/4885LMNA 3299/4885 |
| US-20170313648-A1 | NOVEL PSEUDOCERAMIDE COMPOUND, AND EXTERNAL USE SKIN PREPARATION COMPOSITION CONTAINING SAME | CERS2, CERT1, ACER2 | ALDH1A1 3495/4885TDP1 3962/4885LMNA 3078/4885 |
| US-10233143-B2 | Pseudoceramide compound, and external use skin preparation composition containing same | CERS2, CERT1, ACER2 | ALDH1A1 3161/4885TDP1 3918/4885LMNA 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.